Natixis Advisors
CAI

Natixis Advisors’s Caris Life Sciences CAI Stock Holding History

Natixis Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883K Buy
49,587
+35,828
+260% +$641K ﹤0.01% 1540
2026
Q1 		$246K Buy
+13,759
New +$301K ﹤0.01% 1666

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Natixis Advisors's CAI Position: Q2 2026 in Review

Natixis Advisors increased its Caris Life Sciences (CAI) stake by 260% in Q2 2026, buying an estimated $641K and bringing the position to 49,587 shares worth $883K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

Natixis Advisors first reported a position in CAI in Q1 2026 and has held it in 2 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Natixis Advisors held 49,587 shares of Caris Life Sciences worth $883K as of Q2 2026.
  • Natixis Advisors bought 35,828 Caris Life Sciences shares in Q2 2026, an estimated $641K.
  • Caris Life Sciences made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1540 holding.
  • Natixis Advisors first reported a position in Caris Life Sciences in Q1 2026 and has held it in 2 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.